Here's Why You Should Hold HUN Stock in Your Portfolio Now

Huntsman’s Q2 2026 Polyurethanes revenue rose 16% year over year and adjusted EBITDA more than doubled to $66 million, while Advanced Materials revenue increased 19% and EBITDA rose 42%. Its cost-reduction program reached a $120 million annualized run rate, and the proposed all-stock Olin merger cleared the U.S. HSR waiting period, with expected synergies above $400 million and closing targeted for H1 2027. Offsetting these positives, HUN faces weak construction demand, tariff uncertainty, and volatile benzene and European natural-gas costs; Q3 adjusted EBITDA guidance is $100-$130 million.

Analysis

The investable issue is not the near-term cost program but whether the proposed combination converts two cyclical earnings streams into a structurally lower-cost platform before the cycle turns. Olin's chlor-alkali/feedstock position should improve internal supply economics and reduce Huntsman's exposure to externally purchased inputs, while Huntsman's downstream mix raises the merged entity's margin quality. The synergy target is therefore potentially conservative only if asset rationalization extends beyond headquarters costs; overlapping logistics, procurement and European manufacturing capacity offer a second wave of savings over 12-24 months.

Near term, HUN remains a weak standalone catalyst: price increases can protect dollars but typically lag benzene and European gas shocks by a quarter, and weak construction limits volume leverage. A China MDI price relapse would matter more than headline global pricing because it can trigger export pressure into Europe, compressing regional spreads. The key 1-3 month test is whether EBITDA lands within guidance without incremental working-capital consumption; a miss driven by volume, rather than input costs, would challenge the recovery thesis.

Consensus may be over-crediting the regulatory milestone as equivalent to closing certainty. Remaining approvals could require divestitures or behavioral remedies that dilute the feedstock-integration logic, while an all-stock structure leaves HUN holders exposed to OLN's more commodity-sensitive chlorine and epoxy cycle. Conversely, the market may be underestimating a post-close rerating if management demonstrates that specialty downstream earnings can stabilize the combined company's trough free cash flow; this is a 6-18 month thesis, not a quarterly trade.

Key Decisions for Investors

• Maintain a modest long OLN / short HUN merger-spread position only after calculating the exchange ratio, implied spread and borrow cost; target a 6-12 month horizon. Add if the annualized spread exceeds 15% with no new regulatory remedy signal; exit if required divestitures impair projected synergies or closing slips beyond the first half of 2027.
• Do not add standalone HUN exposure ahead of the next earnings release. Use the report as a catalyst gate: initiate only if EBITDA is at least mid-guidance, downstream margins hold despite raw-material inflation, and management confirms no material cash-cost escalation; otherwise expect multiple compression from another delayed recovery.
• For cyclical materials exposure over 3-6 months, prefer IOSP over HUN: IOSP's specialty additives model has less direct construction and MDI-spread sensitivity. Hedge broad chemicals beta with a partial short XLB if European gas or benzene continues rising.
• Set alerts on China MDI pricing, Northwest European natural gas, and HUN working capital. A renewed China price decline, gas spike, or inventory-led cash burn would falsify the margin-resilience thesis and warrants reducing any HUN or merger-arbitrage exposure.